Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $113.43 USD
Change Today +1.32 / 1.18%
Volume 350.8K
PBYI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

puma biotechnology inc (PBYI) Snapshot

Open
$110.15
Previous Close
$112.11
Day High
$114.87
Day Low
$110.00
52 Week High
08/26/14 - $279.37
52 Week Low
07/18/14 - $57.25
Market Cap
3.6B
Average Volume 10 Days
701.5K
EPS TTM
$-5.71
Shares Outstanding
32.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PUMA BIOTECHNOLOGY INC (PBYI)

puma biotechnology inc (PBYI) Related Businessweek News

No Related Businessweek News Found

puma biotechnology inc (PBYI) Details

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

122 Employees
Last Reported Date: 05/11/15
Founded in 2010

puma biotechnology inc (PBYI) Top Compensated Officers

Founder, Chairman of The Board, Chief Executi...
Total Annual Compensation: $910.0K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $421.9K
Senior Vice President of Clinical Research an...
Total Annual Compensation: $475.8K
Compensation as of Fiscal Year 2014.

puma biotechnology inc (PBYI) Key Developments

Puma Biotechnology, Inc.(NYSE:PBYI) added to Russell 1000 Index

Puma Biotechnology, Inc. has been added to Russell 1000 Index.

Puma Biotechnology, Inc.(NYSE:PBYI) dropped from Russell 2000 Index

Puma Biotechnology, Inc. will be removed from Russell 2000 Index

The Rosen Law Firm Announces the Filing of Securities Class Action Against Puma Biotechnology Inc. to Recover Investor Losses

The Rosen Law Firm, P.A. announced that a class action lawsuit has been filed on behalf of all purchasers of Puma Biotechnology Inc. common stock during the period of July 23, 2014 through May 13, 2015. The lawsuit seeks to recover investors’ losses under the federal securities laws. The complaint alleges that Puma made false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business, operations, prospects and performance. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) the Company’s NDA filing would be for a positive early stage breast cancer indication, instead of the previously announced metastatic breast cancer; (2) Puma would need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which Puma did not have; (3) the additional required studies would necessarily push the time for filing the NDA into the first quarter of 2016; (4) the Company overstated results from its Phase III ExteNET Trial; and (5) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including in its financial statements and about the ongoing ExteNET trial. When the true details entered the market, the lawsuit claims that investors suffered damages.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PBYI:US $113.43 USD +1.32

PBYI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PBYI.
View Industry Companies
 

Industry Analysis

PBYI

Industry Average

Valuation PBYI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PUMA BIOTECHNOLOGY INC, please visit www.pumabiotechnology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.